↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
PE is paying 4x in seven years for a menopause and fertility platform while broader pharma multiples compress — the demo trade has a bid.
£2.2 billion
marking the third private equity ownership change for the…
4x
multiple on the
£550 million
valuation when Carlyle and PAI bought the business from…
90 countries
with a portfolio concentrated in hormone replacement therapy
Cinven acquired Theramex from Carlyle and PAI Partners for approximately £2.2 billion, marking the third private equity ownership change for the women's health pharmaceutical platform since 2018. The price represents a 4x multiple on the £550 million valuation when Carlyle and PAI bought the business from Nordic Capital seven years ago.
Theramex operates across 90 countries with a portfolio concentrated in hormone replacement therapy, contraception, and fertility treatments. Revenue reached approximately £320 million in the twelve months ending September 2024, up from roughly £180 million at the time of the 2018 transaction. The company employs 650 people and maintains manufacturing facilities in France and the United Kingdom. Carlyle and PAI held the asset for 84 months, a duration that sits above the 60-72 month average for European healthcare buyouts closed between 2017 and 2019.
The valuation expansion occurs against a backdrop of compressed multiples in broader pharmaceutical services, where median enterprise value-to-EBITDA ratios have declined from 14.2x in early 2022 to approximately 11.8x as of March 2025. Women's health platforms have resisted this contraction. Three comparable transactions in the past 18 months — including Permira's acquisition of Ferring Pharmaceuticals' reproductive health division and KKR's investment in CooperSurgical — priced above 13x trailing EBITDA. The demographic weight is simple: 47 million women in Europe and North America entered perimenopause between 2020 and 2024, and prescription rates for HRT increased 38% over the same period in the UK alone.
Cinven's thesis centers on geographic expansion and product line extension rather than operational turnaround. The firm has allocated approximately €4.8 billion to healthcare investments since 2020, with 60% of that capital directed toward platforms serving aging female populations. Theramex's existing footprint in Southern Europe and the UK positions it for near-term expansion into Germany and Scandinavia, where regulatory frameworks for telemedicine-enabled HRT prescriptions loosened materially in 2023 and 2024. The company has 12 products in late-stage clinical development, including two menopause-related therapies expected to reach market in 2026.
Allocators should track three developments over the next 24 months: Cinven's approach to bolt-on M&A in the fertility diagnostics segment, where four privately held European targets with revenues between €30 million and €80 million are currently in sell-side processes; the company's manufacturing footprint decisions as UK-EU pharmaceutical trade protocols continue to shift; and the timing of any margin expansion initiatives, given that Theramex's EBITDA margin of approximately 28% sits below the 32-35% range typical of scaled women's health platforms.
Carlyle opened its exit process in Q4 2024, running a dual-track auction that included preliminary conversations with three strategic buyers. None submitted bids above £1.9 billion.
Branded by POPS4 · proof in 60 seconds
For the principal
Women's health platforms are trading at 2022 multiples while everything else deflated — allocate accordingly or miss the demographic inevitability.
For the operator
Track Cinven's bolt-on M&A in fertility diagnostics over the next 18 months — four European targets between €30-80 million revenue are live.
For the house
We are long European women's health exposure through our Permira co-investment; Theramex validates the thesis at a price we would not pay.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.